These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1469 related articles for article (PubMed ID: 33712270)

  • 41. Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Type 1 Cardiorenal Syndrome.
    Ilges DT; Dermody ML; Blankenship C; Mansfield V; Van Tuyl JS
    J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):611-618. PubMed ID: 34138673
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on in-hospital mortality among patients with COVID-19: a systematic review and meta-analysis.
    Cai XJ; Tay JCK; Kui SL; Tin AS; Tan VH
    Singapore Med J; 2021 Nov; 62(11):563-567. PubMed ID: 33256355
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
    Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
    J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
    Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q
    Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367
    [TBL] [Abstract][Full Text] [Related]  

  • 45. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.
    COVID-19 RISk and Treatments (CORIST) Collaboration
    Vascul Pharmacol; 2020 Dec; 135():106805. PubMed ID: 32992048
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients With Coronavirus Disease 2019: Friend or Foe?
    Shyh GI; Nawarskas JJ; Cheng-Lai A
    Cardiol Rev; 2020; 28(4):213-216. PubMed ID: 32496364
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
    Pathak JV; Dass EE
    Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety of ACEi and ARB in COVID-19 management: A retrospective analysis.
    Kumar S; Nikravesh M; Chukwuemeka U; Randazzo M; Flores P; Choday P; Raja A; Aseri M; Shivang S; Chaudhuri S; Barve P
    Clin Cardiol; 2022 Jul; 45(7):759-766. PubMed ID: 35481554
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of outpatient use of renin-angiotensin-aldosterone system blockers on outcomes of acute respiratory illness during the COVID-19 pandemic: a cohort study.
    Jeffery MM; Oliveira J E Silva L; Bellolio F; Garovic VD; Dempsey TM; Limper A; Cummins NW
    BMJ Open; 2022 Jul; 12(7):e060305. PubMed ID: 35793915
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association Between Baseline Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Death Among Patients Tested for COVID-19.
    Thomas SA; Puskarich M; Pulia MS; Meltzer AC; Camargo CA; Courtney DM; Nordenholz KE; Kline JA; Kabrhel C
    J Clin Pharmacol; 2022 Jun; 62(6):777-782. PubMed ID: 34921684
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Positive association of angiotensin II receptor blockers, not angiotensin-converting enzyme inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia.
    Georges JL; Gilles F; Cochet H; Bertrand A; De Tournemire M; Monguillon V; Pasqualini M; Prevot A; Roger G; Saba J; Soltani J; Koukabi-Fradelizi M; Beressi JP; Laureana C; Prost JF; Livarek B
    PLoS One; 2020; 15(12):e0244349. PubMed ID: 33347477
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of the patterns of use of medications with mortality of COVID-19 infection: a hospital-based observational study.
    Wallace AW; Cirillo PM; Ryan JC; Krigbaum NY; Badathala A; Cohn BA
    BMJ Open; 2021 Dec; 11(12):e050051. PubMed ID: 34972763
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.
    Xu J; Huang C; Fan G; Liu Z; Shang L; Zhou F; Wang Y; Yu J; Yang L; Xie K; Huang Z; Huang L; Gu X; Li H; Zhang Y; Wang Y; Hayden FG; Horby PW; Cao B; Wang C
    Front Med; 2020 Oct; 14(5):601-612. PubMed ID: 32621202
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China.
    Li J; Wang X; Chen J; Zhang H; Deng A
    JAMA Cardiol; 2020 Jul; 5(7):825-830. PubMed ID: 32324209
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Angiotensin converting enzyme 2 at the interface between renin-angiotensin system inhibition and coronavirus disease 2019.
    Siri-Angkul N; Chattipakorn SC; Chattipakorn N
    J Physiol; 2020 Oct; 598(19):4181-4195. PubMed ID: 32710575
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis.
    Flacco ME; Acuti Martellucci C; Bravi F; Parruti G; Cappadona R; Mascitelli A; Manfredini R; Mantovani LG; Manzoli L
    Heart; 2020 Oct; 106(19):1519-1524. PubMed ID: 32611676
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.
    ; Lawler PR; Derde LPG; van de Veerdonk FL; McVerry BJ; Huang DT; Berry LR; Lorenzi E; van Kimmenade R; Gommans F; Vaduganathan M; Leaf DE; Baron RM; Kim EY; Frankfurter C; Epelman S; Kwan Y; Grieve R; O'Neill S; Sadique Z; Puskarich M; Marshall JC; Higgins AM; Mouncey PR; Rowan KM; Al-Beidh F; Annane D; Arabi YM; Au C; Beane A; van Bentum-Puijk W; Bonten MJM; Bradbury CA; Brunkhorst FM; Burrell A; Buzgau A; Buxton M; Cecconi M; Cheng AC; Cove M; Detry MA; Estcourt LJ; Ezekowitz J; Fitzgerald M; Gattas D; Godoy LC; Goossens H; Haniffa R; Harrison DA; Hills T; Horvat CM; Ichihara N; Lamontagne F; Linstrum KM; McAuley DF; McGlothlin A; McGuinness SP; McQuilten Z; Murthy S; Nichol AD; Owen DRJ; Parke RL; Parker JC; Pollock KM; Reyes LF; Saito H; Santos MS; Saunders CT; Seymour CW; Shankar-Hari M; Singh V; Turgeon AF; Turner AM; Zarychanski R; Green C; Lewis RJ; Angus DC; Berry S; Gordon AC; McArthur CJ; Webb SA
    JAMA; 2023 Apr; 329(14):1183-1196. PubMed ID: 37039790
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry.
    López-Otero D; López-Pais J; Cacho-Antonio CE; Antúnez-Muiños PJ; González-Ferrero T; Pérez-Poza M; Otero-García Ó; Díaz-Fernández B; Bastos-Fernández M; Bouzas-Cruz N; Sanmartín-Pena XC; Varela-Román A; Portela-Romero M; Valdés-Cuadrado L; Pose-Reino A; González-Juanatey JR
    Rev Esp Cardiol (Engl Ed); 2021 Feb; 74(2):175-182. PubMed ID: 32600991
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction.
    Savarese G; Edner M; Dahlström U; Perrone-Filardi P; Hage C; Cosentino F; Lund LH
    Int J Cardiol; 2015 Nov; 199():415-23. PubMed ID: 26247798
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome.
    Lam KW; Chow KW; Vo J; Hou W; Li H; Richman PS; Mallipattu SK; Skopicki HA; Singer AJ; Duong TQ
    J Infect Dis; 2020 Sep; 222(8):1256-1264. PubMed ID: 32702098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 74.